Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/38355
Title: | Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy. | Authors: | Vlahos R.;Luong R.;Halls M.L.;Reading P.C.;King P.T.;Chan C.;Drummond G.R.;Sobey C.G.;Broughton B.R.S.;Starkey M.R.;Van Der Sluis R.;Lewin S.R.;Bozinovski S.;O'Neill L.A.J.;Quach T.;Porter C.J.H.;Brooks D.A.;O'Leary J.J.;Selemidis S.;To E.E. | Institution: | (To, Vlahos, Bozinovski, Selemidis) Program in Chronic Infectious and Inflammatory Diseases, School of Health and Biomedical Sciences, College of Science, Engineering and Health, RMIT University, Bundoora, VIC 3083, Australia (To, Luong, Chan, Broughton, Selemidis) Department of Pharmacology, Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia (Halls) Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia (Reading) Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia (King) Monash Lung and Sleep, Department of Medicine, Monash Medical Centre, Monash University, Clayton, VIC 3168, Australia (Chan) Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA 02114, United States (Drummond, Sobey) Department of Physiology, Anatomy and Microbiology, School of Life Sciences, La Trobe University, Melbourne, VIC 3086, Australia (Starkey) Priority Research Centre's Grow Up Well and Healthy Lungs, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW 2305, Australia (Van Der Sluis, Lewin) Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, VIC 3000, Australia (Lewin) Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne 3004, Australia (O'Neill) School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland (Quach, Porter) ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia (Quach) Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia (Quach, Porter) Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia (Brooks) School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, Division of Health Sciences, University of South Australia, Adelaide 5001, Australia (O'Leary) Discipline of Histopathology, School of Medicine, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin, Ireland (O'Leary) Sir Patrick Dun's Laboratory, Central Pathology Laboratory, St James's Hospital, Dublin 8, Ireland (O'Leary) Molecular Pathology Laboratory, Coombe Women and Infants University Hospital, Dublin 8, Ireland | Issue Date: | 24-Jul-2017 | Copyright year: | 2017 | Publisher: | Nature Publishing Group | Place of publication: | United Kingdom | Publication information: | Nature Communications. 8 (1) (no pagination), 2017. Article Number: 69. Date of Publication: 01 Dec 2017. | Journal: | Nature Communications | Abstract: | The imminent threat of viral epidemics and pandemics dictates a need for therapeutic approaches that target viral pathology irrespective of the infecting strain. Reactive oxygen species are ancient processes that protect plants, fungi and animals against invading pathogens including bacteria. However, in mammals reactive oxygen species production paradoxically promotes virus pathogenicity by mechanisms not yet defined. Here we identify that the primary enzymatic source of reactive oxygen species, NOX2 oxidase, is activated by single stranded RNA and DNA viruses in endocytic compartments resulting in endosomal hydrogen peroxide generation, which suppresses antiviral and humoral signaling networks via modification of a unique, highly conserved cysteine residue (Cys98) on Toll-like receptor-7. Accordingly, targeted inhibition of endosomal reactive oxygen species production abrogates influenza A virus pathogenicity. We conclude that endosomal reactive oxygen species promote fundamental molecular mechanisms of viral pathogenicity, and the specific targeting of this pathogenic process with endosomal-targeted reactive oxygen species inhibitors has implications for the treatment of viral disease.Copyright © 2017 The Author(s). | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1038/s41467-017-00057-x | ORCID: | Porter, Christopher J. H.; ORCID: http://orcid.org/0000-0003-3474-7551 | PubMed URL: | 28701733 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28701733] | ISSN: | 2041-1723 (electronic) | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/38355 | Type: | Article |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.